Venture capital firm Frazier Healthcare Partners has spun out a US-based antibiotics developer with the help of grant funding from a Boston University-operated body and a $8.5m series A round.

Building on research by a former University of Minnesota professor, Torigen Pharmaceuticals has begun in-veterinary testing of its immunooncology vaccine for companion animals.

UPMC and Kaiser Permanente have returned to contribute to a $100m series F round for the healthcare software developer, which has now achieved a valuation of more than $1bn.

Dianomi Therapeutics will work with Ligand on a medication delivery platform based on research from University of Wisconsin-Madison initially targeting pain disorders and osteoarthritis.

GV and WuXi NextCode both returned to back a $68m round for DNANexus, bringing the biomedical informatics platform’s total funding to approximately $173m.

The meditation app developer has quadrupled its valuation to $1bn in just eight months, in an $88m series B round featuring CAA.

The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.

Sanofi, UCB, Horizon Health Services and McKesson Ventures added $27m to a series B round for the medical data software provider that already included Amgen Ventures.

Samsung Next has taken part in a series B round that will fund the roll out of Healthy.io's home urinalysis analyser system in the UK and expansion in the US.

The molecular diagnostics equipment provider has completed a $11.3m investment from China-based Autobio Diagnostics that was announced in December.